Electronic hookah (waterpipe) vaping reduces vascular endothelial function: the role of nicotine.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

To determine the role of changes in circulating factors in plasma on endothelial cell function, human umbilical vein endothelial cells (HUVECs) were cultured with participants' plasma, and acetylcholine-stimulated nitric oxide (NO) production and basal reactive oxygen species (ROS) bioactivity were assessed.

Why It Was Studied

Vaping has risen substantially in recent years, particularly among young adults.

Electronic (e-) hookahs are a newer category of vaping devices touted as safer tobacco alternatives.

Who Took Part

The abstract describes 18 adults taking part.

By PubMed's age tags, the people studied were young adults.

How the Study Was Run

In design terms this was a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

Plasma nicotine was measured before and after the sessions.

What Was Measured

In a randomized crossover study, the researchers investigated the acute effects of vaping e-hookah, with and without nicotine, as compared with sham on endothelial function assessed by brachial artery flow-mediated dilation (FMD), among 18 overtly healthy young adults.

The subject headings attached to it are Vaping, Nicotine, Smoking Water Pipes, Endothelial Cells, Reactive Oxygen Species, Water Pipe Smoking and Electronic Nicotine Delivery Systems.

The authors tagged it with the keywords electronic hookah, endothelial dysfunction, nitric oxide and oxidative stress.

What This Means in Plain Language

The paper is a randomized and crossover study of Therapeutic nicotine (patch, non-peptide) in 18 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (American journal of physiology. Heart and circulatory physiology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.